FDA Issues Complete Response Letter to sBLA for Xgeva

Amgen announced that it received a complete response letter from the FDA for it supplemental Biologics License Application (sBLA) for Xgeva (denosumab) injection for the treatment of men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

The FDA declined to approve the application because it was determined that the effect on bone metastases-free survival (BMFS) was of insufficient magnitude to outweigh the risks (including osteonecrosis of the jaw) of Xgeva in the intended population.

Xgeva, a RANK ligand inhibitor, is currently approved for the prevention of skeletal-related events (SRE) in patients with bone metastases from solid tumors.

For more information call (800) 772-6436 or visit www.xgeva.com.

You must be a registered member of ONA to post a comment.

April Contest

Click here to get started

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs